Insulin resistance with impaired fasting glucose increases the risk of NAFLD

Kristina Önnerhag, Peter M. Nilsson, Stefan Lindgren

Department of Clinical Sciences, Lund University, Sk?ne University Hospital, Malm?, Sweden.
Department of Gastroenterology and Hepatology, Sk?ne University Hospital, Malm?, Sweden.
Department of Gastroenterology and Hepatology, Sk?ne University Hospital, Malm?, Sweden;Department of Clinical Sciences, Lund University, Sk?ne University Hospital, Malm?, Sweden.

DOI: 10.4236/ojgas.2013.33028                

Abstract

Background: Our aim was to investigate the frequency of elevated liver enzymes and NAFLD in patients with known insulin resistance during 15 years of follow-up. Methods: Subjects with insulin resistance were identified from a population-based prospective cohort study in Sweden, Malm? Diet and Cancer Study, conducted in 1991-1996. Inall, 285 non-diabetic subjects with insulin resistance established by HOMA-IR (homeostasis model assessment) were invited to do the liver function testing and if elevated, they should be further assessed by radiological examination of the liver, anthropometric measures and blood testing. Results: 165 subjects (57.9%) agreed to do the liver function testing. Of these, 25 subjects (15%) had elevated liver enzymes. After exclusion of other diseases, 5 of the remaining 21 subjects (23.8%) had radiological signs of steatosis. Liver steatosis significantly correlated with ALT (alanine aminotransferase) (p = 0.04), HOMA-IR (p = 0.00) and the metabolic syndrome (p = 0.03). 80% of the subjects with NAFLD had either developed type 2 diabetes mellitus or had impaired fasting glucose and 80% fulfilled the WHO-criteria for the metabolic syndrome, which were of significant differences to the group without NAFLD. Conclusion: The risk of developing elevated liver enzymes and NAFLD at long-term follow-up in insulin resistant subjects is not insignificant, but mainly associated with the simultaneous development of impaired fasting glucose, established diabetes mellitus and/ or the metabolic syndrome.

Keywords

Insulin Resistance; Metabolic Syndrome; NAFLD; Steatosis

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Angulo, P. (2002) Nonalcoholic fatty liver disease. New England Journal of Medicine, 346, 1221-1231. doi:10.1056/NEJMra011775
[2]	Sass, D.A., Chang, P. and Chopra, K.B. (2005) Nonalcoholic fatty liver disease: A clinical review. Digestive Diseases and Sciences, 50, 171-180. doi:10.1007/s10620-005-1267-z
[3]	Blachier, M., Leleu, H., Peck-Radosavljevic, M., Valla, D.C. and Roudot-Thoraval, F. (2013) The burden of liver disease in Europe: A review of available epidemiological data. Journal of Hepatology, 58, 593-608. doi:10.1016/j.jhep.2012.12.005
[4]	Torres, D.M., Williams, C.D. and Harrison, S.A. (2012) Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clinical Gastroenterology and Hepatology, 10, 837-858. doi:10.1016/j.cgh.2012.03.011
[5]	Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., et al. (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology, 37, 917-923. doi:10.1053/jhep.2003.50161
[6]	Balkau, B., Charles, M.A., Drivsholm, T., Borch-Johnsen, K., Wareham, N., Yudkin, J.S., et al. (2002) Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes & Metabolism, 28, 364-376.
[7]	Eckel, R.H., Grundy, S.M. and Zimmet, P.Z. (2005) The metabolic syndrome. Lancet, 365, 1415-1428. doi:10.1016/S0140-6736(05)66378-7
[8]	Hernaez, R., Lazo, M., Bonekamp, S., Kamel, I., Brancati, F.L., Guallar, E., et al. (2011) Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta-analysis. Hepatology, 54, 1082-1090. doi:10.1002/hep.24452
[9]	Schwenzer, N.F., Springer, F., Schraml, C., Stefan, N., Machann, J. and Schick, F. (2009) Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. Journal of Hepatology, 51, 433-445. doi:10.1016/j.jhep.2009.05.023
[10]	Schindhelm, R.K., Diamant, M., Dekker, J.M., Tushuizen, M.E., Teerlink, T. and Heine, R.J. (2006) Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes/Metabolism: Research and Reviews, 22, 437-443. doi:10.1002/dmrr.666
[11]	Fracanzani, A.L., Valenti, L., Bugianesi, E., Andreoletti, M., Colli, A., Vanni, E., et al. (2008) Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes. Hepatology, 48, 792-798. doi:10.1002/hep.22429
[12]	Mofrad, P., Contos, M.J., Haque, M., Sargeant, C., Fisher, R.A., Luketic, V.A., et al. (2003) Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology, 37, 1286-1292. doi:10.1053/jhep.2003.50229
[13]	Bugianesi, E., Leone, N., Vanni, E., Marchesini, G., Brunello, F., Carucci, P., et al. (2002) Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology, 123, 134-140. doi:10.1053/gast.2002.34168
[14]	Caldwell, S.H. and Crespo, D.M. (2004) The spectrum expanded: Cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. Journal of Hepatology, 40, 578-584. doi:10.1016/j.jhep.2004.02.013
[15]	Brunt, E.M. and Tiniakos, D.G. (2010) Histopathology of nonalcoholic fatty liver disease. World Journal of Gastroenteroly, 16, 5286-5296. doi:10.3748/wjg.v16.i42.5286
[16]	Dam-Larsen, S., Franzmann, M., Andersen, I.B., Christoffersen, P., Jensen, L.B., Sorensen, T.I., et al. (2004) Long term prognosis of fatty liver: Risk of chronic liver disease and death. Gut, 53, 750-755. doi:10.1136/gut.2003.019984
[17]	Farrell, G.C. and Larter, C.Z. (2006) Nonalcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology, 43, S99-S112. doi:10.1002/hep.20973
[18]	Haque, M. and Sanyal, A.J. (2002) The metabolic abnormalities associated with non-alcoholic fatty liver disease. Best Practice & Research Clinical Gastroenterology, 16, 709-731. doi:10.1053/bega.2002.0325
[19]	Day, C.P. (2002) Pathogenesis of steatohepatitis. Best Practice & Research Clinical Gastroenterology, 16, 663-678. doi:10.1053/bega.2002.0333
[20]	Fracanzani, A.L., Valenti, L., Bugianesi, E., Vanni, E., Grieco, A., Miele, L., et al. (2011) Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity. Journal of Hepatology, 54, 1244-1249. doi:10.1016/j.jhep.2010.09.037
[21]	Eguchi, Y., Mizuta, T., Sumida, Y., Ishibashi, E., Kitajima, Y., Isoda, H., et al. (2011) The pathological role of visceral fat accumulation in steatosis, inflammation, and progression of nonalcoholic fatty liver disease. Journal of Gastroenterology, 46, 70-78. doi:10.1007/s00535-010-0340-3
[22]	Bonora, E., Kiechl, S., Willeit, J., Oberhollenzer, F., Egger, G., Targher, G., et al. (1998) Prevalence of insulin resistance in metabolic disorders: The Bruneck Study. Diabetes, 47, 1643-1649. doi:10.2337/diabetes.47.10.1643
[23]	Hedblad, B., Nilsson, P., Engstrom, G., Berglund, G. and Janzon, L. (2002) Insulin resistance in non-diabetic subjects is associated with increased incidence of myocardial infarction and death. Diabetic Medicine, 19, 470-475. doi:10.1046/j.1464-5491.2002.00719.x
[24]	Nilsson, P.M., Engstrom, G., Hedblad, B., Frystyk, J., Persson, M.M., Berglund, G., et al. (2006) Plasma adiponectin levels in relation to carotid intima media thickness and markers of insulin resistance. Arteriosclerosis, Thrombosis and Vascular Biology, 26, 2758-2762. doi:10.1161/01.ATV.0000249638.01416.4b
[25]	Mathiesen, U.L., Franzen, L.E., Fryden, A., Foberg, U. and Bodemar, G. (1999) The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. Scandinavian Journal of Gastroenterology, 34, 85-91. doi:10.1080/00365529950172880
[26]	Bugianesi, E., McCullough, A.J. and Marchesini, G. (2005) Insulin resistance: A metabolic pathway to chronic liver disease. Hepatology, 42, 987-1000. doi:10.1002/hep.20920
[27]	Leclercq, I.A., Da Silva Morais, A., Schroyen, B., Van Hul, N. and Geerts, A. (2007) Insulin resistance in heaptocytes and sinusoidal liver cells: mechanisms and consequences. Journal of Hepatology, 47, 142-156. doi:10.1016/j.jhep.2007.04.002
[28]	Tilg, H. and Moschen, A.R. (2008) Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends in Endocrinology & Metabolism, 19, 371-379. doi:10.1016/j.tem.2008.08.005
[29]	Wallace, T.M., Levy, J.C. and Matthews, D.R. (2004) Use and abuse of HOMA modeling. Diabetes Care, 27, 1487-1495. doi:10.2337/diacare.27.6.1487
[30]	Rhee, E.J., Lee, W.Y., Cho, Y.K., Kim, B.I. and Sung, K.C. (2011) Hyperinsulinemia and the development of nonalcoholic Fatty liver disease in nondiabetic adults. American Journal of Medicine, 124, 69-76. doi:10.1016/j.amjmed.2010.08.012
[31]	Ekstedt, M., Franzen, L.E., Mathiesen, U.L., Thorelius, L., Holmqvist, M., Bodemar, G., et al. (2006) Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology, 44, 865-873. doi:10.1002/hep.21327